Tubulis Stock

Tubulis Technologies generates uniquely matched protein-drug conjugates.

Sign up today and learn more about Tubulis Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Tubulis Stock

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.

Funding History

July 2017$1.3M
July 2020$10.7M
May 2022$60.0M
March 2024$128M



Ingo Lehrke

Board Member

Sebastian Pünzeler

Board Member

Kanishka Pothula

Board Member

Jan Van den Bossche

Founder, CEO

Dominik Schumacher

Chief Development Officer

Björn Hock

Board Member

Valentin Piech

Board Member

Sofia Ioannidou

Board Member

Thomas Hanke

Founder, CSO

Jonas Helma

Board Observer

Annegret de Baey

Board Member

Christoph Broja

Board Observer

Lena Krzyzak


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: